MV-4-11 cells are macrophages that were isolated from the blast cells of a child with biphenotypic B-myelomonocytic leukemia and can be used in cancer and immunology research.

Origins and properties of hematopoietic growth factor-dependent cell lines. The t (4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.

细胞描述:MV-4-11 细胞系由Rovera 课题组建立,来源于一名患有人双表型髓性单核细胞白血病(biphenotypic B myelomonocytic leukemia)的 10 岁男孩的外周血。 Interleukin (IL)-3 可以独立地支持该细胞长期生长, 使用10%FBS 培养时则不需要额外添加IL-3。 但是,在 IL-3 和生长因子Granulocyte/Macrophage Colony-Stimulating Factor(GM-CSF)均处于低浓度的情况下,IL-3 会 …

The MV4-11 carries t(4;11) (q21;q23), typically observed in biphenotypic congenital leukemias and +8, +9 . The presence of t(4;11) typically characterizes a subgroup of acute childhood leukemias, suggesting potential application in studying these disease entities [168,169,170].

2022年2月15日 · Momelotinib shows high efficacy against FLT3-mutated AML cells, including quizartinib-resistant activation loop variants. Momelotinib effectively suppresses intrinsic resistance conferred by FLT3 ligand and hematopoietic cytokines (GM-CSF and IL-3).

MV4-11 cells harvested from tissue culture flasks are implanted into the subcutaneous space of the left flank of the mice. Resulting tumors are monitored by calipering twice weekly. Animal weights are measured three times weekly. Animal behaviour is monitored daily.

2018年10月7日 · MV4-11 is a human AML cell line established from blasts cells of 10 years old male with biphenotypic B-myelomonocytic leukemia (AML FAB M5) that carry translocation t (4;11) and a FLT3 -ITD mutation.

For human tumor cell lines immune-compromised mice are used with the advantage to study classical antitumoral test compounds. In contrast, murine tumor cell lines can be grown in immune-competent mice (syngeneic), providing a functional immune system to assess novel immunotherapeutic approaches. PCF ing. LN ax./br. Ileum.

2022年2月25日 · Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy.

Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy.